Evidence map›Paper›PMID 41134458›Full record

Trial reportClinical autonomic research : official journal of the Clinical Autonomic Research Society2026

Establishing minimally clinically important differences for the orthostatic hypotension questionnaire (OHQ).

Horacio Kaufmann, Jose-Alberto Palma, Ross Vickery, Lucy Norcliffe-Kaufmann, Beiyao Zheng, David Lewin, Tadhg Guerin

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Orthostatic hypotension and acute cognitive dysfunction in Parkinson's disease: insights from functional near-infrared spectroscopy.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2026
    Article
  3. From "evidence is scarce" to trial-ready care pathways in POTS: an audit-ready roadmap prompted by Schiweck et al.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2026
    Article
  4. Autonomic debate: symptoms are an optimal target for orthostatic hypotension screening and management. An argument in opposition.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2026
    Article
  5. Symptoms are an optimal target for orthostatic hypotension screening and management: an argument in favor.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Horacio KaufmannDepartment of Neurology, New York University School of Medicine, New York, NY, USA.
Jose-Alberto PalmaDepartment of Neurology, New York University School of Medicine, New York, NY, USA.
Ross VickeryTheravance Biopharma Ireland Limited, 51 South Richmond Street, Dublin, D02 FK02, Ireland.
Lucy Norcliffe-KaufmannDepartment of Neurology, New York University School of Medicine, New York, NY, USA.
Beiyao ZhengTheravance Biopharma US, LLC, South San Francisco, CA, USA.
David LewinTheravance Biopharma US, LLC, South San Francisco, CA, USA.
Tadhg GuerinTheravance Biopharma Ireland Limited, 51 South Richmond Street, Dublin, D02 FK02, Ireland. TGuerin@theravance.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEstablish the minimally clinically important difference (MCID) for the Orthostatic Hypotension Questionnaire (OHQ).

backgroundNeurogenic orthostatic hypotension (nOH) causes disabling symptoms that impair daily function and quality of life. The OHQ is a validated patient-reported outcome with a symptom assessment (OHSA) and daily activity scale (OHDAS), widely used in clinical trials, despite the MCID being unestablished.

methodsWe analyzed data from two phase 3, randomized placebo-controlled trials (SEQUOIA and REDWOOD), evaluating ampreloxetine for symptomatic nOH in patients with Parkinson disease, multiple system atrophy, and pure autonomic failure. Using anchor-based and distribution-based methods, we calculated the MCID for the total OHQ score, OHSA and OHDAS composite subscales, and for the single dizziness/lightheadedness question (OHSA1).

resultsThe analysis included 184 subjects from SEQUOIA and 128 from REDWOOD. The total OHQ MCID for improvement was a reduction of 0.9-1.2 points and for worsening was an increase of 0.7-1.1 points. The MCID for the OHSA composite ranged from a reduction of 0.9-1.3 points for improvement and an increase of 0.7-1.1 points for worsening. For the single-item OHSA1, the MCID was a reduction of 2.0-3.0 points for improvement and an increase of 1.0 point for worsening. Owing to poor correlation with the symptom-based anchors, a reliable MCID for the OHDAS component was not established.

conclusionsThese MCID thresholds for the OHQ, OHSA and OHSA item 1 alone, enhance the interpretability of scores and support their use in evaluating clinical benefit.

Indexed as

Hypotension, OrthostaticMinimal Clinically Important DifferenceAgedFemaleHumansMaleMiddle AgedParkinson DiseasePatient Reported Outcome MeasuresQuality of LifeSurveys and QuestionnairesAutonomic nervous systemClinical trialMinimal clinically important differenceOrthostatic hypotensionPatient-reported outcome

Identifiers

PMID41134458
PMCPMC12982295

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.